Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK570445PMID: 34014626
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2022215-59-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of dostarlimab during breastfeeding. Because dostarlimab is a large protein molecule with a molecular weight of about 144,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for 4 months after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Dostarlimab
CAS Registry Number
2022215-59-2
Drug Class
Breast Feeding
Lactation
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Gemtuzumab Ozogamicin.[Drugs and Lactation Database (...]Review Gemtuzumab Ozogamicin.. Drugs and Lactation Database (LactMed®). 2006
- Review Loncastuximab Tesirine.[Drugs and Lactation Database (...]Review Loncastuximab Tesirine.. Drugs and Lactation Database (LactMed®). 2006
- Review Sacituzumab Govitecan.[Drugs and Lactation Database (...]Review Sacituzumab Govitecan.. Drugs and Lactation Database (LactMed®). 2006
- Review Enfortumab Vedotin.[Drugs and Lactation Database (...]Review Enfortumab Vedotin.. Drugs and Lactation Database (LactMed®). 2006
- Review Inotuzumab Ozogamicin.[Drugs and Lactation Database (...]Review Inotuzumab Ozogamicin.. Drugs and Lactation Database (LactMed®). 2006
- Dostarlimab - Drugs and Lactation Database (LactMed®)Dostarlimab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...